At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Subjects With IgE >= 30 IU/mL
In Brief
A Phase 1 clinical trial evaluating Placebo, Omalizumab, and 6 other interventions for Allergic Asthma and 3 related conditions. Completed, enrolled 295 participants across 7 sites.
Detailed Summary
Phase 1 study to evaluate the safety of MEDI4212.
Study Details
Timeline
Interventions
A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.